黑色素瘤免疫治疗作用机制研究进展

doi:10.19586/j.2095-2341.2023.0094

生物技术进展 ›› 2023, Vol. 13 ›› Issue (6): 900-906.DOI: 10.19586/j.2095-2341.2023.0094

• 进展评述 • 上一篇

黑色素瘤免疫治疗作用机制研究进展

张鹏晓¹(), 胡念²()

^1.上海理工大学健康科学与工程学院，上海 200093
^2.上海健康医学院附属第六人民医院南院，上海 201499

收稿日期:2023-07-28 接受日期:2023-08-29 出版日期:2023-11-25 发布日期:2023-12-12
通讯作者: 胡念
作者简介:张鹏晓E-mail: pengxiao031699@163.com；
基金资助:
上海市生物医药科技支撑专项(21S11902000)

The Research Progress on Action Mechanism of Melanoma Immunotherapy

Pengxiao ZHANG¹(), Nian HU²()

^1.School of Health Science and Engineering，University of Shanghai for Science and Technology，Shanghai 200093，China
^2.Shanghai University of Medicine & Health Sciences Affiliated Sixth People’s Hospital South Campus，Shanghai 201499，China

Received:2023-07-28 Accepted:2023-08-29 Online:2023-11-25 Published:2023-12-12
Contact: Nian HU

摘要/Abstract

摘要：

皮肤癌是临床中皮肤科常见的恶性肿瘤，以皮肤恶性黑色素瘤（cutaneous malignant melanoma, CM）侵袭性最强。随着人们生活习惯的改变，黑色素瘤的发病率逐渐升高，其发病主要与紫外线辐射引起黑色素细胞突变有关，具有极强的免疫原性，研究CM的发生发展机制对于疾病的治疗至关重要。对皮肤恶性黑色素瘤的免疫治疗及其相关作用机制的研究进行了综述，以期为黑色素瘤的治疗提供新的思路。

关键词: 黑色素瘤, 靶向治疗, 免疫检查点抑制剂, 肿瘤微环境

Abstract:

Skin cancer is a common malignant tumor in dermatology in clinical practice， and among which cutaneous malignant melanoma （CM） is the most aggressive one. With the change of people's lifestyle， the incidence of melanoma is gradually increasing， and its development is mainly related to the mutation of melanocytes caused by ultraviolet radiation， which is extremely immunogenicity， and the study of the mechanism of CM development is crucial for the treatment of the disease. This article reviewed the research on immunotherapy of cutaneous malignant melanoma and its related mechanisms of action， with the aim of providing a new way of thinking about the treatment of melanoma.

Key words: melanoma, targeted therapy, immune checkpoint inhibitors, tumor microenvironment

中图分类号:

Q939.91

张鹏晓, 胡念. 黑色素瘤免疫治疗作用机制研究进展[J]. 生物技术进展, 2023, 13(6): 900-906.

Pengxiao ZHANG, Nian HU. The Research Progress on Action Mechanism of Melanoma Immunotherapy[J]. Current Biotechnology, 2023, 13(6): 900-906.

参考文献 42

1	TÍMÁR J, LADÁNYI A. Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction[J/OL]. Int. J. Mol. Sci., 2022, 23(10): 5384[2023-06-20]. .
2	GANDINI S, AUTIER P, BONIOL M. Reviews on sun exposure and artificial light and melanoma[J]. Prog. Biophys. Mol. Biol., 2011, 107(3): 362-366.
3	WHITEMAN D, GREEN A. The pathogenesis of melanoma induced by ultraviolet radiation[J]. Ann. Coloproctol., 1999, 341(10): 766-767.
4	MONTI M, CONSOLI F, VESCOVI R, et al.. Human plasmacytoid dendritic cells and cutaneous melanoma[J/OL]. Cells, 2020, 9(2): E417[2023-06-20]. .
5	LEE C, COLLICHIO F, OLLILA D, et al.. Historical review of melanoma treatment and outcomes[J]. Clin. Dermatol., 2013, 31(2): 141-147.
6	SCHREIBER R D, OLD L J, SMYTH M J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
7	BRADLEY S D, CHEN Z, MELENDEZ B, et al.. BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8⁺ T-cell recognition of melanoma[J]. Cancer Immunol. Res., 2015, 3(6): 602-609.
8	JACQUELOT N, BELZ G T. Type 2 innate lymphoid cells: a novel actor in anti-melanoma immunity[J/OL]. Oncoimmunology, 2021, 10(1): 1943168[2023-06-20]. .
9	MARZAGALLI M, EBELT N D, MANUEL E R. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment[J]. Semin. Cancer Biol., 2019, 59: 236-250.
10	ZHANG Y, KURUPATI R, LIU L, et al.. Enhancing CD8⁽⁺⁾ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy[J]. Cancer Cell, 2017, 32(3): 377-391.
11	CHANG C H, QIU J, O'SULLIVAN D, et al.. Metabolic competition in the tumor microenvironment is a driver of cancer progression[J]. Cell, 2015, 162(6): 1229-1241.
12	CROCI D O, ZACARÍAS FLUCK M F, RICO M J, et al.. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment[J]. Cancer Immunol. Immunother., 2007, 56(11): 1687-1700.
13	CHEN Y, YI X, SUN N, et al.. Epigenetics regulates antitumor immunity in melanoma[J/OL]. Front. Immunol., 2022, 13: 868786[2023-06-20]. .
14	CANALE F P, RAMELLO M C, NÚÑEZ N, et al.. CD39 expression defines cell exhaustion in tumor-infiltrating CD8⁺T cells-response[J/OL]. Cancer Res., 2018, 78(17): 5175[2023-06-20]. .
15	EYVAZI S, KAZEMI B, DASTMALCHI S, et al.. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy[J]. Curr. Cancer Drug Targets, 2018, 18(4): 328-336.
16	PRICE M A, COLVIN WANSHURA L E, YANG J, et al.. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma[J]. Anal. Chem., 2011, 24(6): 1148-1157.
17	WANG X, OSADA T, WANG Y, et al.. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer[J]. J. Natl. Cancer Inst., 2010, 102(19): 1496-1512.
18	TORISU-ITAKURA H, SCHOELLHAMMER H F, SIM M S, et al.. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells[J]. J. Immunother. Hagerstown Md., 2011, 34(8): 597-605.
19	TOKI M I, MERRITT C R, WONG P F, et al.. High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling[J]. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2019, 25(18): 5503-5512.
20	DOMINGUES B, LOPES J M, SOARES P, et al.. Melanoma treatment in review[J]. Immuno Targets Ther., 2018, 7: 35-49.
21	GUBIN M M, ZHANG X, SCHUSTER H, et al.. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J]. Nature, 2014, 515(7528): 577-581.
22	WOLCHOK J D, KLUGER H, CALLAHAN M K,et al.. Nivolumab plus ipilimumab in advanced melanoma[J]. N. Engl. J. Med., 2013,369(2):122-133.
23	HAMID O, ROBERT C, DAUD A, et al.. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl. J. Med., 2013, 369(2): 134-144.
24	TOPALIAN S L, HODI F S, BRAHMER J R, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N. Engl. J. Med., 2012, 366(26): 2443-2454.
25	BAGCHI S, YUAN R, ENGLEMAN E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu. Rev. Pathol., 2021, 16: 223-249.
26	ROTTE A, JIN J Y, LEMAIRE V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy[J]. Ann. Oncol., 2018, 29(1): 71-83.
27	MARGOLIS N, MARKOVITS E, MARKEL G. Reprogramming lymphocytes for the treatment of melanoma: from biology to therapy[J]. Adv. Drug Deliv. Rev., 2019, 141: 104-124.
28	BALD T, LANDSBERG J, LOPEZ-RAMOS D, et al.. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation[J]. Cancer Discov., 2014, 4(6): 674-687.
29	TUMEH P C, HARVIEW C L, YEARLEY J H, et al.. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528): 568-571.
30	HODI F S, O'DAY S J, MCDERMOTT D F, et al.. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N. Engl. J. Med., 2010, 363(8): 711-723.
31	SHUBHRA S, JASON R, NEERAJ S, et al.. B cells are required to generate optimal anti-melanoma immunity in response to checkpoint blockade[J]. Front. Immunol.,2022,13: 941-941.
32	ZHAO F, XIAO C, EVANS K S, et al.. Paracrine Wnt5a-β-catenin signaling triggers a metabolic program that drives dendritic cell tolerization[J]. Immunity, 2018, 48(1): 147-160.
33	KHAN W N, WRIGHT J A, KLEIMAN E, et al.. B-lymphocyte tolerance and effector function in immunity and autoimmunity[J]. Immunol. Res., 2013, 57(1-3): 335-353.
34	GILES J R, KASHGARIAN M, KONI P A, et al.. B cell-specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus[J]. J. Immunol., 2015, 195(6): 2571-2579.
35	KOBAYASHI T, OISHI K, OKAMURA A, et al.. Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting T helper type 1 cytokine production in tumor-infiltrating CD8(+) T cells[J]. J. Invest. Dermatol., 2019, 139(7): 1535-1544.
36	RODRÍGUEZ-CERDEIRA C, CARNERO GREGORIO M, LÓPEZ-BARCENAS A, et al.. Advances in immunotherapy for melanoma: a comprehensive review[J/OL]. Mediators Inflamm., 2017, 2017: 3264217[2023-06-20]. .
37	WEBER R, RIESTER Z, HÜSER L, et al.. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma[J/OL]. J. Immunother. Cancer, 2020, 8(2): e000949[2023-06-20]. .
38	KUMARI N, DWARAKANATH B S, DAS A, et al.. Role of interleukin-6 in cancer progression and therapeutic resistance[J]. Tumour Biol., 2016, 37(9): 11553-11572.
39	ZHANG C, ZHANG X, CHEN X H. Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance[J]. Clin. Rev. Allergy Immunol., 2014, 47(2): 163-173.
40	TROVATO R, FIORE A, SARTORI S, et al.. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3[J/OL]. J. Immunother. Cancer, 2019, 7(1): 255[2023-06-20]. .
41	KNIGHT A, KARAPETYAN L, KIRKWOOD J M. Immunotherapy in melanoma: recent advances and future directions[J/OL]. Cancers, 2023, 15(4): 1106[2023-06-20]. .
42	FU Y H, XIAO W, MAO Y X. Recent advances and challenges in uveal melanoma immunotherapy[J/OL]. Cancers,2022,14(13):3094[2023-11-20]. .

[1]	杜琳琳, 谢飞, 马雪梅. SALL4的促癌功能及治疗意义[J]. 生物技术进展, 2023, 13(5): 704-711.
[2]	李永超, 杨昭. 双特异抗体药物研发现状及发展对策[J]. 生物技术进展, 2023, 13(3): 353-358.
[3]	王林琳, 孙振亮. 氨基酸转运体在肿瘤代谢中的研究进展[J]. 生物技术进展, 2022, 12(1): 50-56.
[4]	肖金平, 李程, 曹云娣, 孙志坚, 康平, 兰晓梅. RET原癌基因与肿瘤相关性研究的进展现状[J]. 生物技术进展, 2022, 12(1): 57-62.

黑色素瘤免疫治疗作用机制研究进展

The Research Progress on Action Mechanism of Melanoma Immunotherapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 4

编辑推荐

Metrics

本文评价